



**Sangamo BioSciences, Inc.**  
Point Richmond Tech Center  
501 Canal Blvd., Suite A100  
Richmond, CA 94804  
510-970-6000 • 510-236-8951(Fax)

---

## **SANGAMO BIOSCIENCES PRESENTS DATA ON INDUCIBLE REGULATION OF AN ENDOGENOUS GENE USING A “SWITCHABLE” ENGINEERED TRANSCRIPTION FACTOR**

**Boston, MA** – June 7, 2002 – Sangamo BioSciences, Inc. (NASDAQ: SGMO) will present data today describing approaches that it has developed to enable small molecule control of endogenous gene expression. These data will be presented in a talk given by Sangamo scientist Dr. Carolyn Dent in the Regulated Gene Expression: Novel Technologies Session (Abstract # 510) at the 5th Annual Meeting of the American Society of Gene Therapy.

The presentation will include the first demonstration of inducible regulation of an endogenous gene using a zinc finger DNA binding protein transcription factor (ZFP TF) that can be “switched on” or made active by treatment with a small molecule. The studies use a “switchable” ZFP TF (32E-hPRLBD-p65) that contains the Valentis GeneSwitch<sup>®</sup> gene regulation system, incorporating a progesterone receptor ligand-binding domain. The inclusion of the GeneSwitch<sup>®</sup> regulatory domain fused to the engineered ZFP TF allows the transcription factor to be “switched” to an active form capable of regulating its endogenous target gene. Activation of the ZFP TF and the subsequent regulation of its endogenous target gene, in this case activation of the human vascular endothelial growth factor gene (VEGF), is only achieved by the addition of mifepristone, a small molecule antiprogesterin. VEGF activation is not detected in the absence of the drug. The studies show that the levels of activation of the VEGF gene by 32E-hPRLBD-p65 show a clear dose-response to mifepristone. The system was also shown to be effective in a variety of cell types.

“The Valentis GeneSwitch<sup>®</sup> system is well-validated. By using this element in a novel way in combination with our ZFP-TF technology we have expanded its application and now have a powerful way to precisely regulate the cell’s own genes, using a “switchable ZFP TF” and an orally administered drug,” said Dr. Carl Pabo, Sangamo’s senior vice president and chief scientific officer. “The capability for regulatable expression is important in a gene therapy application as it allows control of both the duration of the exposure to the therapeutic agent and gives the flexibility of more precise dosing.”

Work will also be presented describing studies by Sangamo scientists on the use of inducible expression of ZFP TFs to effect regulation of the endogenous gene. For this work a doxycyclin inducible system has been used.

### **About Sangamo**

Sangamo BioSciences, Inc., of Richmond, CA, is focused on the research and development of novel transcription factors for the regulation of gene expression. The company’s most advanced therapeutic development program involves the use of transcription factors for the treatment of cardiovascular disease. Other therapeutics development programs are focused on cancer and infectious diseases. Sangamo’s proprietary technology enables the engineering of transcription factors known as zinc finger DNA-binding proteins, or ZFPs. By engineering ZFPs so that they can recognize a specific gene, Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. The company is developing ZFP TFs as a fundamentally enabling technology for commercial applications in human therapeutics, pharmaceutical discovery, clinical diagnostics, agriculture and industrial biotechnology. Over twenty leading pharmaceutical and biotechnology companies have utilized ZFP TFs. For more information about Sangamo, visit the company’s web site at [www.sangamo.com](http://www.sangamo.com).

**Sangamo BioSciences, Inc.**  
Point Richmond Tech Center  
501 Canal Blvd., Suite A100  
Richmond, CA 94804  
510-970-6000 • 510-236-8951(Fax)

---

*This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and applications of Sangamo's ZFP TF technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, our ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.*

Contact: Elizabeth Wolffe, Ph.D.  
510-970-6000, x271

###